These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23552278)

  • 1. An acute neurological syndrome with cerebrovascular and parkinsonian clinical features associated with perioperative SNRI withdrawal.
    Williams GW; Gandhi SJ; Altamirano A
    J Neurosurg Anesthesiol; 2013 Jul; 25(3):353-4. PubMed ID: 23552278
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
    Leo RJ; Brooks VL
    Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 4. Milnacipran for fibromyalgia.
    Dempsey J
    Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
    Bernstein CD; Albrecht KL; Marcus DA
    Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin syndrome after administration of milnacipran for fibromyalgia.
    Yacoub HA; Johnson WG; Souayah N
    Neurology; 2010 Feb; 74(8):699-700. PubMed ID: 20177126
    [No Abstract]   [Full Text] [Related]  

  • 7. Milnacipran for neuropathic pain and fibromyalgia in adults.
    Derry S; Gill D; Phillips T; Moore RA
    Cochrane Database Syst Rev; 2012 Mar; 3(3):CD008244. PubMed ID: 22419330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACS chemical neuroscience molecule spotlight on savella.
    Hopkins CR
    ACS Chem Neurosci; 2010 May; 1(5):345. PubMed ID: 22778830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran].
    Koshiishi T; Okuyama K
    Yakugaku Zasshi; 2016; 136(12):1675-1679. PubMed ID: 27904101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levomilnacipran (Fetzima) a new SNRI for depression.
    Med Lett Drugs Ther; 2013 Dec; 55(1432):101-2. PubMed ID: 24419243
    [No Abstract]   [Full Text] [Related]  

  • 12. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
    Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
    Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's syndrome in a patient treated with milnacipran.
    Bourgade B; Jonville-Béra AP; Le Garé C; Ferquel D; Autret-Leca E
    Ann Pharmacother; 1999 Sep; 33(9):1009-10. PubMed ID: 10492510
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
    Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
    Owen RT
    Drugs Today (Barc); 2008 Sep; 44(9):653-60. PubMed ID: 19137120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
    Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.
    Branco JC; Cherin P; Montagne A; Bouroubi A;
    J Rheumatol; 2011 Jul; 38(7):1403-12. PubMed ID: 21459941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.